Peptide therapeutics for rare genetic metabolic diseases

Rhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Year Invested: 2010
Location: Boston, Mass.

Recent News

February 16, 2017
Rhythm Announces Completion of $41 Million Mezzanine Financing

November 4, 2016
Rhythm Presents Positive Initial Data for Setmelanotide in LepR Deficiency Obesity

September 19, 2016
FierceBiotech Names Rhythm as a “Fierce 15” Biotechnology Company of 2016

Read More News

Associated Team Members

Neil Exter